Further studies are necessary to determine the prevalence of pathogenic germline ATM variants in patients with IPMN that have not had surgical resections and the magnitude of the risk of progression to PDAC associated with pathogenic germline ATM variants in patients with IPMN. This evidence concerns the gene ATM and pancreatic intraductal papillary-mucinous neoplasm.